Clinical Trial Update: Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study of pembrolizumab with gemcitabine and cisplatin as neoadjuvant therapy for bladder cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-08-10